This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2017
  • /
  • 12
  • /
  • NICE rejects Scenesse as not cost effective
Drug news

NICE rejects Scenesse as not cost effective

Read time: 1 mins
Last updated:21st Dec 2017
Published:21st Dec 2017
Source: Pharmawand

The National Institute for Health and Care Excellence (NICE) has in preliminary guidance rejected Scenesse (afamelanotide) a dissolving implant from Clinuvel Pharma, to treat erythropoietic protoporphyria, an inherited disorder affecting some 500-600 patients in England. NICE considered that the benefit of Scenesse was unclear from the evidence and that the product was not cost effective.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.